NASDAQ:ENGN enGene Q2 2025 Earnings Report $2.97 +0.09 (+3.13%) As of 02:56 PM Eastern Earnings HistoryForecast enGene EPS ResultsActual EPSN/AConsensus EPS -$0.48Beat/MissN/AOne Year Ago EPSN/AenGene Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AenGene Announcement DetailsQuarterQ2 2025Date6/10/2025TimeBefore Market OpensConference Call DateFriday, June 13, 2025Conference Call Time12:00AM ETConference Call ResourcesEarnings HistoryCompany Profile enGene Earnings HeadlinesUS Pratt engine strikers press for jobs commitment, union saysMay 9, 2025 | msn.comBrokerages Set enGene Holdings Inc. (NASDAQ:ENGN) PT at $23.29May 8, 2025 | americanbankingnews.comFed’s New Plan: They Could Freeze Your AccountThe Fed's Plan to Control Your Money Is Live! While everyone is focused on tariffs and inflation, the Federal Reserve is quietly rolling out a new program that could give them unprecedented control over your bank account. This isn't a rumor—it's all laid out in Federal Reserve Docket No. OP-1670, a 93-page document that reveals their plan to monitor and control your finances to shield yourself. In this free Wealth Defense Guide, we'll show you 3 simple steps to shield your money from the Fed's overreach and keep your savings safe.May 14, 2025 | Priority Gold (Ad)Common Problems With The BMW B48 Engine (According To Owners)May 7, 2025 | msn.com9 Of The Best Diesel Engines Ever Made By American CompaniesMay 6, 2025 | msn.comGM’s V8 Engine Problem Is So Bad It’s Wrecking Thousands Of Trucks And SUVsApril 30, 2025 | msn.comSee More enGene Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like enGene? Sign up for Earnings360's daily newsletter to receive timely earnings updates on enGene and other key companies, straight to your email. Email Address About enGeneenGene (NASDAQ:ENGN), through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.View enGene ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles D-Wave Pushes Back on Short Seller Case With Strong EarningsAppLovin Surges on Earnings: What's Next for This Tech Standout?Can Shopify Stock Make a Comeback After an Earnings Sell-Off?Rocket Lab: Earnings Miss But Neutron Momentum HoldsWhy Nearly 20 Analysts Raised Meta Price Targets Post-EarningsOXY Stock Rebound Begins Following Solid Earnings BeatMonolithic Power Systems: Will Strong Earnings Spark a Recovery? Upcoming Earnings Copart (5/15/2025)NetEase (5/15/2025)Applied Materials (5/15/2025)Mizuho Financial Group (5/15/2025)National Grid (5/15/2025)Walmart (5/15/2025)Alibaba Group (5/15/2025)Deere & Company (5/15/2025)Palo Alto Networks (5/19/2025)PDD (5/20/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
